Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals (XENE) PT Raised to $8 at Jefferies Following New Epilepsy Asset

May 10, 2017 10:35 AM EDT

Jefferies raised its price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $8.00 (from $7.00) while maintaining a Buy rating. The company added a new epilepsy asset, XEN1101, to their portfolio.

TV-45070 topline results are expected mid-2017. An IND for '901 is planned for 4Q17, and... More